Christophe Giot
Vice President, Global Medical Affairs Vicore Pharma Holding
Christophe Giot, MD, is Vice President, Global Medical Affairs at Vicore Pharma, bringing more than 20 years of international leadership experience across medical affairs, clinical development, and cardiology-driven innovation. A board-certified interventional cardiologist trained at the University of Brussels, he began his career in clinical practice before transitioning into global pharmaceutical and medtech leadership roles.
Dr. Giot has held senior positions at companies including Sanofi, Bristol Myers Squibb, and Actelion, building deep expertise across cardiology, immunology, liver disease, and rare diseases. During his time at InterMune (later acquired by Roche), he contributed to the launch of the first approved therapy for idiopathic pulmonary fibrosis, a landmark moment in the field.
More recently, he has led medical and clinical affairs in both established and emerging biotech environments, including first-in-human programmes, regulatory submissions, and early feasibility studies in structural heart disease. At Vicore, he is focused on advancing medical strategy in fibrosis, strengthening global KOL engagement, and building scientific partnerships to accelerate development in IPF and other fibrotic lung diseases.
Seminars
- Exploring how dysfunction of alveolar type 2 (AEC2) cells drives loss of lung integrity and initiates fibrotic remodeling, positioning epithelial repair as a novel therapeutic strategy
- Understanding how angiotensin II type 2 receptor agonists (ATRAGs), including buloxibutid, activate protective signaling pathways to promote alveolar repair, restore tissue homeostasis, and reduce fibrotic progression
- Reviewing the design of the global, randomized, placebo controlled ASPIRE study evaluating buloxibutid over 52 weeks, including its focus on FVC outcomes, background standard-of-care integration, and potential to demonstrate disease-modifying effects in IPF
